Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 11/20/2017 8:03:34 PM - Followers: 727 - Board type: Free - Posts Today: 81

Innovation Pharmaceuticals Inc. (IPIX)

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564

About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at


Ongoing Human Trials:
Product Pipeline:





Recent News and Press Releases:

SEC Filings (CIK:0001355250):

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f

Share Structure:  See SEC filing link above for current share structure


Cellceutix IP - Patent Filings:


Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:

Following is a DAILY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
#203170  Sticky Note Doesn't seem at all reasonable that any person DaysOnTheBeach 11/09/17 10:51:58 AM
#202469  Sticky Note B-OM Due Diligence sox040713 11/03/17 04:42:35 PM
#200759  Sticky Note IPIX is looking for partnerships after P2's. petemantx 10/19/17 10:14:05 PM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#204436   Why are you in two startup phamas (two Pepperchino 11/20/17 08:03:34 PM
#204435   simple logic, ok, how's this imo: untohim 11/20/17 07:59:53 PM
#204434   Gambling means you could lose money. Which stock doesn't? sox040713 11/20/17 07:49:45 PM
#204433   excellent response. TheHound 11/20/17 07:47:27 PM
#204432   Lol. Excellent. Thanks for FINRA’s response. Matagordaville 11/20/17 07:46:59 PM
#204431   a european partner perhaps...someone did say ipix meant untohim 11/20/17 07:46:21 PM
#204430   Maybe dual partnerships. US and Europe with DaubersUP 11/20/17 07:43:12 PM
#204429   Normal market making functions usually represent a large % groton68 11/20/17 07:37:20 PM
#204428   Not just me. FINRA thinks the daily short sox040713 11/20/17 07:29:42 PM
#204427   Some of these partnering conversations have matured to untohim 11/20/17 07:27:12 PM
#204426   36k unloaded at close....results getting close getting closer imo untohim 11/20/17 07:13:36 PM
#204425   There's absolutely no indication in his daily report loanranger 11/20/17 07:10:44 PM
#204424   I didn't suggest IPIX will be the next sox040713 11/20/17 07:10:36 PM
#204423   Biotech investing is also called as gambling. Many Amatuer17 11/20/17 07:04:52 PM
#204422   The trading algorithm for the stock market is sox040713 11/20/17 07:03:23 PM
#204421   Polymedix did not partnership and went down the Amatuer17 11/20/17 07:02:09 PM
#204419   I don't think that's the correct way to sox040713 11/20/17 06:43:16 PM
#204417   getting the hang of it! buy each day untohim 11/20/17 06:37:31 PM
#204416   Whether it's in the source file or not loanranger 11/20/17 06:35:30 PM
#204415   They(IPIX) announced final tment of the last patient kfcyahoo 11/20/17 06:32:14 PM
#204414   Parked on the .7 bid all day isn’t LilBigKahuna 11/20/17 06:31:10 PM
#204413   Whether FINRA have to or don't have to sox040713 11/20/17 06:30:43 PM
#204412   "FINRA didn't say "15% of today's volume was loanranger 11/20/17 06:20:28 PM
#204411   Pharmacyclics didn't get their first partnership until the sox040713 11/20/17 06:18:43 PM
#204409   New investors, FINRA didn't say "15% of today's sox040713 11/20/17 05:50:56 PM
#204407   FINRA short sales of IPIX AlanC 11/20/17 05:44:28 PM
#204406   Just sitting back having a couple of cold tryz 11/20/17 05:28:28 PM
#204405   Just some fine tuning before the Rolex roll out. Blue Fin 11/20/17 05:23:32 PM
#204398   but not down near as much as you Williamsc 11/20/17 04:18:41 PM
#204395   It's called "investing" not a get rich quick Williamsc 11/20/17 04:11:12 PM
#204394   One of my elite subscribers gobbled up shares scottsmith 11/20/17 04:06:59 PM
#204393   Today was a complete disaster. Down 4% MXAMDUD 11/20/17 04:02:52 PM
#204392   Comparing to EFT, really? Buy one in that Topspin17 11/20/17 03:55:13 PM
#204391   Nobody lost money here because of B. In Williamsc 11/20/17 03:54:57 PM
#204390   The tic toc has also become very weak Amatuer17 11/20/17 03:46:07 PM
#204389   yawn. we've been hearing that forever. MXAMDUD 11/20/17 03:43:33 PM
#204388   I can only think you are being blinded bradfordbros 11/20/17 03:38:19 PM
#204387   That is some kind of thinking. As far BooDog 11/20/17 03:32:09 PM
#204386   Nearly every month since Jan 2016 I see Amatuer17 11/20/17 03:28:17 PM
#204385   As you have been saying for last 2+ Amatuer17 11/20/17 03:25:29 PM
#204384   Nice add tryz, time is running out for BooDog 11/20/17 03:25:12 PM
#204383   Brilacidin ph2 Oral Mucositis results could show up KarinCA 11/20/17 02:59:29 PM
#204382   But what about the 'Testing', The Science, and TheBunny 11/20/17 02:25:55 PM
#204381   I totally agree with you guys (Farrell90 & Echo20). brainlessgoat 11/20/17 02:11:40 PM
#204380   a stopped watch is right twice a day, baytdr 11/20/17 02:07:31 PM
#204379   Looks like three cents is the new nickel TheDane 11/20/17 02:05:52 PM
#204378   they just destroy shareholder capital. MXAMDUD 11/20/17 01:46:45 PM
#204377   IPIX does not care who buys or sells Amatuer17 11/20/17 01:37:43 PM
#204376   Seem plausible that Aspire is content to sit baytdr 11/20/17 12:31:39 PM
#204374   As promised to IPIX....Bought another 5k of company tryz 11/20/17 10:52:23 AM